Targeted stimulation of immune pathway may help body fight back against liver cancer

June 5, 2013
Cancer biology: Awakening the body’s anticancer defenses
The presence of natural killer cells (blue) expressing high levels of TLR3 protein (red) in HCC tumors is associated with a better prognosis and longer patient survival. Inset shows a cluster of natural killer cells with elevated TLR3. Credit: Oxford University Press

Though it originates from the body's own cells, a tumor is as much of a hostile invader as any virus or bacterium. If the immune system is sufficiently sensitized, it can mount a counterattack just as it might fight an infection. For many patients, this response is insufficient, but researchers led by Jean-Pierre Abastado of the A*STAR Singapore Immunology Network have uncovered an immune mechanism that may help patients with hepatocellular carcinoma (HCC) keep their liver cancer at bay.

Certain viral infections stimulate the via the toll-like receptor 3 (TLR3) protein, but TLR3 activation also seems to kill certain cancers. Accordingly, the researchers had previously observed improved odds of survival among Singaporean HCC patients with elevated tumor TLR3 levels. Abastado and co-workers subsequently verified these initial findings in an additional cohort of patients from Hong Kong and Zurich, and demonstrated that increased survival time was associated with high TLR3 levels in both and tumor-infiltrating .

Mouse model experiments demonstrated that TLR3 stimulation causes tumor cells to essentially 'self-destruct', while also recruiting a subset of natural killer (NK) innate immune cells to penetrate and attack the tumor. The remnants of the dead tumor cells further stimulate TLR3 signaling, accelerating the immune counterattack. "The triggering of TLR3 kick-starts a positive feedback loop that creates more cell death, and triggers more activation of TLR3 in both tumor and ," explains Valerie Chew, a in Abastado's laboratory and lead author of the research paper. In addition, TLR3 activation also summons other immune-cell subtypes; the researchers demonstrated that this immune recruitment is critical for tumor reduction in mice.

Analysis of patient HCC tumor samples revealed similar results (see image), where elevated TLR3 activity was associated with high levels of and increased tumor cell death. Why TLR3 levels are elevated in certain patients remains unclear, but Chew hypothesizes that their immune systems may be receiving a boost from certain pathogens. "It is conceivable that co-infection with viruses such as acute influenza may trigger expression of TLR3," she says, "and we believe that mounting an antiviral immune response via TLR3 actually provides protection against cancer."

As an alternative to catching influenza, HCC patients may benefit from TLR3-activating drugs such as Hiltonol, from US pharmaceutical company Oncovir. Hiltonol is in early clinical trials for the treatment of breast cancer and melanoma. Abastado's team is exploring the potential for an HCC trial of Hiltonol in collaboration with Oncovir and Han Chong Toh from Singapore General Hospital.

Explore further: Heightened immunity to colds makes asthma flare-ups worse, research shows

More information: Chew, V. et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. Journal of the National Cancer Institute 104, 1796–1807 (2012).

Related Stories

Brain displays an intrinsic mechanism for fighting infection

November 19, 2012

(Medical Xpress)—White blood cells have long reigned as the heroes of the immune system. When an infection strikes, the cells, produced in bone marrow, race through the blood to fight off the pathogen. But new research ...

Recommended for you

Malaria vaccine provides hope for a general cure for cancer

October 13, 2015

The hunt for a vaccine against malaria in pregnant women has provided an unexpected side benefit for Danish researchers, namely what appears to be an effective weapon against cancer. The scientists behind the vaccine aim ...

Breast cancer drug beats superbug

October 13, 2015

Researchers at University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences have found that the breast cancer drug tamoxifen gives white blood cells a boost, better enabling ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.